School of Pharmacy, Jiangxi University of Chinese Medicine, Nanchang, China.
Clinical Development Department, Shandong Qidu Pharmaceutical Co., Ltd, Zibo, China.
Pharm Biol. 2021 Dec;59(1):1402-1414. doi: 10.1080/13880209.2021.1990353.
Erzhi pills are a classic Chinese medicine prescription, but their effects on Alzheimer's disease (AD) are not clear.
The protective effects of Erzhi pills in AD rats and their potential mechanisms were investigated.
An AD rat model was established by ovariectomy combined with d-galactose and Aβ injection. Rats were randomly divided into five groups: sham-operated, model, oestradiol valerate (0.80 mg/kg), Erzhi pills high-dose (1.50 g/kg), and Erzhi pills low-dose (0.75 g/kg). Learning and memory abilities were evaluated with the Morris water maze test, oestrogen levels with an ELISA kit, and hippocampal neuron morphology and Nissl bodies in the cytoplasm with H&E and Nissl staining. The expression of ERβ, Aβ, and p-tau was determined by immunohistochemistry. Nano LC-LTQ-Orbitrap Proteomics determined potential targets and related signalling pathways. Western blotting was used to detect the expression of the related proteins.
Erzhi pills (1.5, 0.75 g/kg) markedly reduced escape latencies on the MWM, increased numbers of platform crossings, numbers of neurons, Nissl bodies, oestrogen levels (100.18, 43.04 pg/mL), and ERβ-positive cells (57.42, 39.83); Aβ (18.85, 36.83)- and p-tau (14.42, 29.71)-positive cells were significantly decreased. Proteomics identified more than 100 differentially expressed proteins involved in 48 signalling pathways, five of which are involved in the PI3K/Akt signalling pathway. Western blotting showed decreased expression of GSK3β and Bad, while Akt, PI3K, 14-3-3, Bcl-xl, and Bcl-2 were upregulated.
Erzhi pills may serve as a potential agent for AD therapeutics by improving learning and memory.
二至丸对阿尔茨海默病大鼠的保护作用及机制研究
二至丸是一种经典的中药方剂,但对阿尔茨海默病(AD)的作用尚不清楚。
观察二至丸对 AD 大鼠的保护作用并探讨其作用机制。
采用去卵巢联合 D-半乳糖和 Aβ 注射建立 AD 大鼠模型,将大鼠随机分为 5 组:假手术组、模型组、戊酸雌二醇(0.80mg/kg)组、二至丸高剂量(1.50g/kg)组、二至丸低剂量(0.75g/kg)组。Morris 水迷宫实验检测大鼠学习记忆能力,ELISA 试剂盒检测大鼠血清雌激素水平,H&E 和尼氏染色观察海马神经元形态和胞质尼氏体,免疫组化检测 ERβ、Aβ 和 p-tau 表达,纳米液相色谱-线性轨道阱质谱联用技术(nano LC-LTQ-Orbitrap Proteomics)检测潜在作用靶点及相关信号通路,Western blot 检测相关蛋白表达。
二至丸(1.5、0.75g/kg)可明显缩短 AD 大鼠逃避潜伏期,增加平台穿越次数和海马神经元数量及尼氏体数,升高血清雌激素水平(100.18、43.04pg/mL)和 ERβ 阳性细胞数(57.42、39.83),减少 Aβ(18.85、36.83)和 p-tau(14.42、29.71)阳性细胞数。nano LC-LTQ-Orbitrap Proteomics 检测到 100 多个差异表达蛋白,涉及 48 个信号通路,其中 5 个与 PI3K/Akt 信号通路相关。Western blot 结果显示,二至丸可下调 GSK3β和 Bad 表达,上调 Akt、PI3K、14-3-3、Bcl-xl 和 Bcl-2 表达。
二至丸可能通过改善学习记忆能力发挥抗 AD 作用,有望成为治疗 AD 的潜在药物。